Invitation

Precision medicine in NSCLC: novel approaches for targeting KRAS

Friday 26 March 2021 12.50–14.20 CET Channel 2

Drugging the undruggable: the science behind targeting *KRAS*


Professor Mariano Barbacid, Centro Nacional de Investigaciones Oncologicas, Spain

Emerging KRAS-targeted therapies in NSCLC

Professor Martin Schuler University Hospital Essen, Germany

Incorporating *KRAS* as a novel biomarker: challenges and opportunities

Professor Aleš Ryška Charles University, Czech Republic





Oncology

Amgen (Europe) GmbH, 6343 Rotkreuz, Switzerland Date of preparation: February 2021 © 2021 Amgen Inc. All rights reserved.